slides · global inventory
Aida
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 3,551
Current window 2,131-2,160
Pages 119
Rows per page 30
Arc
2,131-2,160 of 3,551
01
Immix Biopharma | Investor Presentation Deck | 58 slidesImmix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Attention1 hit
02
Immix Biopharma | Investor Presentation Deck | 58 slidesImmix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Attention1 hit
03
The slide uses a numbered list format to present key value propositions.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Attention1 hit
04
The slide uses a hub-and-spoke diagram to illustrate the central problem of CAR-T neurotoxicity and its four primary negative outcomes.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
05
Includes a cartoon mascot at the bottom.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
06
The slide uses a visual comparison to highlight the safety advantage of NXC-201, specifically focusing on neurotoxicity and CRS duration.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
07
Uses a visual icon-grid to represent market expansion from 5% of hospitals to a much broader network.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
08
The slide uses a molecular biology diagram to illustrate the structural difference in the binding domain of the NXC-201 therapy compared to competitors.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
09
Includes comparative bar charts and flow cytometry data.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Aha Moment1 hit
10
The slide uses a comparative timeline/chart layout to contrast clinical outcomes of three different therapies.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Aha Moment1 hit
11
The chart demonstrates the efficacy of NXC-201 (formerly HBI0101) in clearing diseased cells.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
12
The slide uses a process flow diagram to connect cellular pathology to clinical symptoms in the heart, liver, and kidneys.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
13
Includes extensive source citations in the footer.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
14
The slide uses a table structure to contrast treatment outcomes and patient growth across three stages of multiple myeloma.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
15
The slide uses a visual comparison to highlight a 67% improvement in response rates for NXC-201 compared to competitors.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
16
Includes FDA approval precedents in the footer to establish credibility.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
17
Includes detailed clinical trial citations in the footer.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
18
The slide uses a two-column layout to separate milestones by drug candidate.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
19
The slide uses a side-by-side comparison structure to explain two distinct but complementary technology platforms.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
20
The table uses a standard pharmaceutical pipeline format, categorizing by clinical vs preclinical status and highlighting specific regulatory and clinical trial milestones.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
21
Combines market sizing data with a 'Why Now' narrative supported by industry news clippings and a comparative efficacy table.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Golden Circle1 hit
22
The slide uses a wave-like visual to represent market segments and their associated valuations.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Golden Circle1 hit
23
Immix Biopharma | Investor Presentation Deck | 58 slidesImmix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
24
The slide uses a red dashed box to highlight the primary efficacy metrics (response rates).Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
25
The chart uses a grouped bar structure to compare efficacy across patient segments (No BCMA, Yes BCMA, Overall).Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
26
The slide uses a comparison table framework to highlight competitive advantage in clinical metrics.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
27
The slide uses a two-column layout to compare clinical data for two different indications, supported by competitor market data.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
28
The chart illustrates deepening responses over time in a clinical trial setting.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
29
The table displays clinical trial data for NXC-201, specifically focusing on Cytokine Release Syndrome (CRS) and Immune cell associated Neurotoxicity (ICANS).Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
34
Uses a numbered list format to present key arguments for the board's re-election.Nano Dimension | Shareholder Engagement Presentation Deck | 34 slides · Nano Dimension
Shareholder letter Investor relations Beat · Action1 hit